The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for SYD-101 (atropine sulfate) to slow the progression of myopia in children. Considered a common ...
If approved, SYD-101 would be the first pharmaceutical treatment to slow the progression of pediatric myopia in the U.S. The FDA accepted a new drug application for SYD-101 to slow the progression ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback